Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
14.52 USD | +1.75% | +4.10% | -33.52% |
May. 09 | Oppenheimer Adjusts Viridian Therapeutics Price Target to $31 From $36, Maintains Outperform Rating | MT |
May. 09 | B. Riley Downgrades Viridian Therapeutics to Neutral From Buy | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-33.52% | 911M | |
+33.35% | 49.46B | |
+1.75% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+11.81% | 26.61B | |
-22.66% | 18.64B | |
+7.85% | 13.16B | |
+29.58% | 12.55B | |
+24.25% | 12.1B |
- Stock Market
- Equities
- VRDN Stock
- News Viridian Therapeutics, Inc.
- Transcript : Miragen Therapeutics, Inc., Viridian Therapeutics, Inc. - M&A Call